Nothing Special   »   [go: up one dir, main page]

MX2021006932A - Receptores de celulas t humanas con alta afinidad modificados por medio de manipulacion genetica. - Google Patents

Receptores de celulas t humanas con alta afinidad modificados por medio de manipulacion genetica.

Info

Publication number
MX2021006932A
MX2021006932A MX2021006932A MX2021006932A MX2021006932A MX 2021006932 A MX2021006932 A MX 2021006932A MX 2021006932 A MX2021006932 A MX 2021006932A MX 2021006932 A MX2021006932 A MX 2021006932A MX 2021006932 A MX2021006932 A MX 2021006932A
Authority
MX
Mexico
Prior art keywords
tcrs
cell receptors
engineered
affinity
affinity human
Prior art date
Application number
MX2021006932A
Other languages
English (en)
Inventor
Sheena N Smith
David M Kranz
Daniel T Harris
Original Assignee
Univ Illinois
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Illinois filed Critical Univ Illinois
Publication of MX2021006932A publication Critical patent/MX2021006932A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se proporcionan receptores de células T (TCR) que tienen mayor afinidad para el antígeno Survivina. Los TCR de alta afinidad se modificaron por medio de manipulación genética a través de la generación de bibliotecas de mutaciones de los TCR en un formato de cadena simple, seguido por una selección para mejorar la estabilidad y afinidad en la superficie de levadura (es decir, evolución dirigida). En algunas realizaciones, los TCR modificados por medio de manipulación genética se pueden utilizar en forma soluble para la administración dirigida in vivo, o como genes introducidos en células T en un entorno de células T adoptivas.
MX2021006932A 2013-11-22 2016-05-20 Receptores de celulas t humanas con alta afinidad modificados por medio de manipulacion genetica. MX2021006932A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361907887P 2013-11-22 2013-11-22

Publications (1)

Publication Number Publication Date
MX2021006932A true MX2021006932A (es) 2021-07-07

Family

ID=53180203

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2016006625A MX2016006625A (es) 2013-11-22 2014-11-21 Receptores de células t humanas con alta afinidad modificados por medio de manipulación genética.
MX2016006620A MX371202B (es) 2013-11-22 2014-11-21 Receptores de células t humanas con alta afinidad modificados por medio de manipulación genética.
MX2021006932A MX2021006932A (es) 2013-11-22 2016-05-20 Receptores de celulas t humanas con alta afinidad modificados por medio de manipulacion genetica.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MX2016006625A MX2016006625A (es) 2013-11-22 2014-11-21 Receptores de células t humanas con alta afinidad modificados por medio de manipulación genética.
MX2016006620A MX371202B (es) 2013-11-22 2014-11-21 Receptores de células t humanas con alta afinidad modificados por medio de manipulación genética.

Country Status (20)

Country Link
US (4) US10344075B2 (es)
EP (2) EP3071594A4 (es)
JP (4) JP6697386B2 (es)
KR (2) KR102415259B1 (es)
CN (2) CN105899530B (es)
AU (4) AU2014352826B2 (es)
BR (1) BR112016011567A2 (es)
CA (2) CA2930852C (es)
DK (1) DK3071593T3 (es)
ES (1) ES2729406T3 (es)
IL (2) IL245467B (es)
MX (3) MX2016006625A (es)
PL (1) PL3071593T3 (es)
PT (1) PT3071593T (es)
RU (2) RU2740648C2 (es)
SA (1) SA516371174B1 (es)
SG (2) SG10201804335QA (es)
TR (1) TR201908404T4 (es)
WO (2) WO2015077615A1 (es)
ZA (2) ZA201603116B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2542141T3 (es) 2005-10-17 2015-07-31 Sloan Kettering Institute For Cancer Research Péptidos WT1 de unión a HLA de clase II, y composiciones y métodos que los comprenden
EP3834836A1 (en) 2006-04-10 2021-06-16 Memorial Sloan Kettering Cancer Center Immunogenic wt-1 peptides and uses thereof
CN108676069A (zh) 2012-01-13 2018-10-19 纪念斯隆凯特林癌症中心 免疫原性wt-1肽及其使用方法
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
SI2945647T1 (sl) 2013-01-15 2021-01-29 Memorial Sloan Kettering Cancer Center Imunogeni peptidi WT-1 in postopki za uporabo le-teh
BR112016011567A2 (pt) 2013-11-22 2017-10-24 Hutchinson Fred Cancer Res receptores de célula t humana de alta afinidade geneticamente modificados.
JP7142571B2 (ja) * 2015-09-22 2022-09-27 ユリウス－マクシミリアン－ウニヴェルシテート・ヴュルツブルク リンパ球における高レベル且つ安定な遺伝子移入のための方法
CN114195882A (zh) * 2015-10-01 2022-03-18 圣拉斐尔医院有限公司 Tcr及其用途
GB201520570D0 (en) * 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
EP3394092A1 (en) * 2015-12-23 2018-10-31 Fred Hutchinson Cancer Research Center High affinity t cell receptors and uses thereof
MA45491A (fr) * 2016-06-27 2019-05-01 Juno Therapeutics Inc Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés
US11534461B2 (en) 2016-11-14 2022-12-27 Fred Hutchinson Cancer Center High affinity merkel cell polyomavirus T antigen-specific TCRS and uses thereof
MX2019010972A (es) * 2017-03-15 2019-12-02 Hutchinson Fred Cancer Res Receptores de linfocito t (tcr) específicos del antígeno asociado a melanoma 1 (mage-a1) de alta afinidad y usos de estos.
TWI835730B (zh) * 2017-04-24 2024-03-21 義大利聖拉斐爾醫院 Ｔｃｒ及肽
JP7181517B2 (ja) * 2018-01-23 2022-12-01 国立大学法人三重大学 Ｔ細胞レセプター
JP2021530546A (ja) * 2018-07-23 2021-11-11 マジェンタ セラピューティクス インコーポレイテッドMagenta Therapeutics, Inc. 同種異系の細胞療法における抗−ｃｄ１３７抗体薬物コンジュゲート（ａｄｃ）の使用
GB201911066D0 (en) 2019-08-02 2019-09-18 Achilles Therapeutics Ltd T cell therapy
US20220409661A1 (en) * 2019-08-20 2022-12-29 Fred Hutchinson Cancer Research Center T-cell immunotherapy specific for wt-1
CA3170403A1 (en) * 2020-02-12 2021-08-19 Abb Vie Inc. Bispecific binding molecules
WO2021219990A1 (en) 2020-04-28 2021-11-04 Achilles Therapeutics Uk Limited T cell therapy
EP4320435A1 (en) 2021-04-09 2024-02-14 Achilles Therapeutics UK Limited Batch release assay for pharmaceutical products relating to t cell therapies
GB202109886D0 (en) 2021-07-08 2021-08-25 Achilles Therapeutics Uk Ltd Assay
KR20240023426A (ko) 2021-06-22 2024-02-21 아킬레스 테라퓨틱스 유케이 리미티드 항원-특이적 t 세포를 생산하는 방법
AU2022314048A1 (en) * 2021-07-19 2024-02-22 Board Of Regents, The University Of Texas System Peptides and engineered t cell receptors targeting fanci, rad51, and pbk antigens and methods of use

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3927193A (en) 1973-05-18 1975-12-16 Hoffmann La Roche Localization of tumors by radiolabelled antibodies
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4348376A (en) 1980-03-03 1982-09-07 Goldenberg Milton David Tumor localization and therapy with labeled anti-CEA antibody
US4361544A (en) 1980-03-03 1982-11-30 Goldenberg Milton David Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4444744A (en) 1980-03-03 1984-04-24 Goldenberg Milton David Tumor localization and therapy with labeled antibodies to cell surface antigens
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4468457A (en) 1981-06-01 1984-08-28 David M. Goldenberg Method for producing a CSAp tryptic peptide and anti-CSAp antibodies
US5101827A (en) 1985-07-05 1992-04-07 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US4640561A (en) 1985-11-15 1987-02-03 Ford Motor Company Flexible printed circuit connector
US5059413A (en) 1988-04-18 1991-10-22 Xoma Corporation Scintigraphic monitoring of immunotoxins using radionuclides and heterobifunctional chelators
ATE172879T1 (de) 1989-08-09 1998-11-15 Rhomed Inc Direkte radioetikettierung von antikörpern und sonstigen proteinen mittels technetium oder rhenium
US5299253A (en) 1992-04-10 1994-03-29 Akzo N.V. Alignment system to overlay abdominal computer aided tomography and magnetic resonance anatomy with single photon emission tomography
US6696251B1 (en) 1996-05-31 2004-02-24 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US6699658B1 (en) 1996-05-31 2004-03-02 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US6300065B1 (en) 1996-05-31 2001-10-09 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US6759243B2 (en) 1998-01-20 2004-07-06 Board Of Trustees Of The University Of Illinois High affinity TCR proteins and methods
EA200001216A1 (ru) 1998-05-19 2001-06-25 Авидекс Лимитед Растворимый т-лимфоцитный рецептор
AU1218000A (en) 1998-10-21 2000-05-08 Sunol Molecular Corporation Polyspecific binding molecules and uses thereof
JP4317940B2 (ja) * 2001-08-31 2009-08-19 イミュノコア・リミテッド 物質
US7892559B2 (en) * 2002-01-30 2011-02-22 Survac Aps Survivin-derived peptides and use thereof
NZ539225A (en) 2002-10-09 2006-09-29 Avidex Ltd Single chain recombinant T cell receptors
GB0304068D0 (en) 2003-02-22 2003-03-26 Avidex Ltd Substances
GB0328363D0 (en) * 2003-12-06 2004-01-14 Imp College Innovations Ltd Therapeutically useful molecules
EP1765860B1 (en) 2004-05-19 2008-12-10 MediGene Ltd. High affinity ny-eso t cell receptor
CA2567349C (en) 2004-05-19 2012-11-27 Avidex Ltd Method of improving t cell receptors
GB0524477D0 (en) 2005-11-30 2006-01-11 Avidex Ltd Isolated T cell receptors which specifically bind to vygfvracl-hla-24
GB0511124D0 (en) 2005-06-01 2005-07-06 Avidex Ltd High affinity melan-a t cell receptors
AT503861B1 (de) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von t-zell-rezeptoren
US8088379B2 (en) 2006-09-26 2012-01-03 The United States Of America As Represented By The Department Of Health And Human Services Modified T cell receptors and related materials and methods
US9281917B2 (en) 2007-01-03 2016-03-08 Nokia Technologies Oy Shared control channel structure
EP2352756B1 (en) 2008-11-24 2012-09-19 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH High affinity t cell receptor and use thereof
WO2010075417A1 (en) 2008-12-23 2010-07-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Survivin specific t cell receptor for treating cancer
US9409969B2 (en) 2009-02-09 2016-08-09 Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh) Repertoire of allo-restricted peptide-specific T cell receptor sequences and use thereof
GB0911566D0 (en) * 2009-07-03 2009-08-12 Immunocore Ltd T cell receptors
CA2777053A1 (en) 2009-10-06 2011-04-14 The Board Of Trustees Of The University Of Illinois Human single-chain t cell receptors
CA2805320A1 (en) 2010-07-28 2012-02-02 Immunocore Ltd T cell receptors
EP3213765B1 (en) 2010-09-20 2019-08-28 BioNTech Cell & Gene Therapies GmbH Antigen-specific t cell receptors and t cell epitopes
KR20150009556A (ko) 2012-05-03 2015-01-26 프레드 헛친슨 켄서 리서치 센터 증강된 친화성 t　세포 수용체 및 이의 제조 방법
WO2014191465A1 (en) * 2013-05-28 2014-12-04 Møller Niels Iversen Peptides derived from lawsonia intracellularis and their use in vaccination
PL228457B1 (pl) 2013-08-30 2018-03-30 Univ Jagiellonski Tomograf hybrydowy TOF-PET/CT
BR112016011567A2 (pt) 2013-11-22 2017-10-24 Hutchinson Fred Cancer Res receptores de célula t humana de alta afinidade geneticamente modificados.
JP6712261B2 (ja) 2014-08-04 2020-06-24 フレッド ハッチンソン キャンサー リサーチ センター Ｗｔ−１に特異的なｔ細胞免疫治療
CN113105562B (zh) * 2018-09-26 2023-12-01 安源医药科技（上海）有限公司 突变型单链人凝血因子viii在制备融合蛋白中的应用

Also Published As

Publication number Publication date
PT3071593T (pt) 2019-06-27
IL245467A0 (en) 2016-06-30
US20190055298A1 (en) 2019-02-21
CA2930852A1 (en) 2015-05-28
WO2015077607A1 (en) 2015-05-28
JP2022023196A (ja) 2022-02-07
RU2016124179A (ru) 2017-12-27
CN105873945B (zh) 2020-07-17
MX2016006625A (es) 2016-12-02
KR20160085345A (ko) 2016-07-15
CA2930852C (en) 2024-01-23
ES2729406T3 (es) 2019-11-04
RU2729383C2 (ru) 2020-08-06
BR112016011567A2 (pt) 2017-10-24
US10344075B2 (en) 2019-07-09
JP6970724B2 (ja) 2021-11-24
US20220396606A1 (en) 2022-12-15
EP3071593A4 (en) 2017-05-03
AU2021202274A1 (en) 2021-05-06
JP6697386B2 (ja) 2020-05-20
BR112016011583A2 (pt) 2017-09-26
NZ719720A (en) 2020-09-25
CA2930847A1 (en) 2015-05-28
US20160280756A1 (en) 2016-09-29
WO2015077615A1 (en) 2015-05-28
RU2016124163A (ru) 2017-12-27
NZ719707A (en) 2020-09-25
RU2740648C2 (ru) 2021-01-19
TR201908404T4 (tr) 2019-07-22
KR102415259B1 (ko) 2022-06-30
JP2020007374A (ja) 2020-01-16
SG10201804335QA (en) 2018-06-28
CN105899530B (zh) 2020-05-08
AU2014352826A1 (en) 2016-05-26
CN105873945A (zh) 2016-08-17
MX371202B (es) 2020-01-22
EP3071594A1 (en) 2016-09-28
AU2019272003B2 (en) 2021-05-06
AU2014352834B2 (en) 2019-08-29
EP3071594A4 (en) 2017-05-03
PL3071593T3 (pl) 2019-11-29
MX2016006620A (es) 2017-05-11
US10023625B2 (en) 2018-07-17
SA516371174B1 (ar) 2019-04-14
KR20160087866A (ko) 2016-07-22
ZA201603169B (en) 2020-05-27
AU2014352826B2 (en) 2019-08-01
JP2017501130A (ja) 2017-01-12
EP3071593B1 (en) 2019-03-13
AU2014352834A1 (en) 2016-05-26
CN105899530A (zh) 2016-08-24
EP3071593A1 (en) 2016-09-28
IL245468B (en) 2020-10-29
US20160280755A1 (en) 2016-09-29
IL245468A0 (en) 2016-06-30
SG10201804330YA (en) 2018-07-30
JP6476182B2 (ja) 2019-02-27
AU2019272003A1 (en) 2019-12-19
IL245467B (en) 2020-04-30
DK3071593T3 (da) 2019-06-11
JP2017501129A (ja) 2017-01-12
ZA201603116B (en) 2018-12-19

Similar Documents

Publication Publication Date Title
MX2021006932A (es) Receptores de celulas t humanas con alta afinidad modificados por medio de manipulacion genetica.
CY1123142T1 (el) Βελτιωμενες μεθοδοι για την παραγωγη θετων κυτταρικων θεραπειων
MA40253A (fr) Cellules modifiées pour thérapie cellulaire adoptive
MX2019000643A (es) Receptores de antigenos quimericos y metodos de uso.
WO2017011804A8 (en) Engineered cells for adoptive cell therapy
PH12014502418A1 (en) Enhanced affinity t cell receptors and methods for making the same
MX2020006689A (es) Composiciones de vcar y metodos de uso.
MX2019013498A (es) Receptor de antigeno quimerico y metodos para usarlo.
MX2023005612A (es) Celulas modificadas que expresan antigeno de membrana especifico de prostata (psma) o una forma modificada del mismo y metodos relacionados.
EA201590488A1 (ru) Способы модификации клеток-хозяев
MX2013008850A (es) Composiciones y metodos para tratar enfermedades cardiovasculares.
EP4279579A3 (en) Methods and compositions for natural killer cells
MY197851A (en) Antibody formulations
MX2014014337A (es) Metodo de produccion de alta concentracion de celulas madre.
MX2018014043A (es) Composiciones de cultivo celular con antioxidantes y metodos para la produccion de polipeptidos.
AU2016335217A8 (en) Antigen receptors and uses thereof
MX2015011781A (es) Medio de cultivo celular y metodos de produccion de anticuerpos.
EP4295914A3 (en) Genetically-engineered drug resistant t cells and methods of using the same
HRP20201177T1 (hr) Terapijsko cjepivo za liječenje dijabetesa tipa 1 kod djece, primjena staničnog sortera i metoda umnožavanja treg stanica za proizvodnju terapijskog cjepiva za liječenje dijabetesa tipa 1
MX350159B (es) Inyecciones mejoradas.
MX2021001981A (es) Metodos para preparar un poloxamero para usar en medio de cultivo celular.
MX365656B (es) Nuevas vacunas contra multiples subtipos del virus del dengue.
WO2016049510A3 (en) Cell-based targeted delivery of pseudonomas exotoxin